1Y Target$3.84Near-term target
5Y Target$5.38Compound horizon
10Y Target$7.91Long-dated conviction
FCF—TTM—FCF not applicable for this sector (bank / insurer / REIT) or data unavailable
Rev+19.7%TTM YoYB+Revenue +19.7% — above sector median, healthy trajectory
D/E——D/E data unavailable — neutral default
P/E37.3xCP/E 37.3 — rich valuation; execution risk material
PEG1.89proxyC+PEG 1.89 — modest premium; above fair value · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Why now
Biotechnology · market cap $1.0b. Down 72% from 52-week high of $11.85 — deep drawdown territory. Revenue growing +20%, comfortably above the S&P median.
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Down 72% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trailing P/E 37x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. Net margin 4.7% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first.
Horizon
1-3 yr $3.84 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $5.38 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $7.91 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.